Radiotherapy in the Treatment of Hereditary Breast Cancer

Seminars in Radiation Oncology

Volumn 21, Issue 1, 2011, Pages 43-50

  Pierce, Lori J ^a   Haffty, Bruce G ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE LKB1; PROTEIN MDM2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DESQUAMATION; DISEASE ASSOCIATION; ERYTHEMA; FAMILIAL CANCER; FATIGUE; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HEART MUSCLE FIBROSIS; HEREDITY; HUMAN; LUNG FIBROSIS; LUNG TOXICITY; MASTALGIA; MASTECTOMY; ONCOGENE; OVARIECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; REVIEW; RIB FRACTURE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LI-FRAUMENI SYNDROME; MASTECTOMY; MASTECTOMY, SEGMENTAL; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; RNA HELICASES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 78649900234     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.08.008     Document Type: Review

References (57)

1. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408.
2. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
3. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002, 94:1365-1372.
4. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997, 349:1505-1510. Breast Cancer Linkage Consortium.
5. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145.
6. Foulkes W.D., Wong N., Brunet J.S., et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997, 3:2465-2469.
7. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91:1310-1316. Breast Cancer Linkage Consortium.
8. Ansquer Y., Gautier C., Fourquet A., et al. Survival in early onset BRCA1 breast cancer patients. Institut Curie Breast Cancer Group. Lancet 1998, 352:541.
9. Robson M.E., Boyd J., Borgen P.I., et al. Hereditary breast cancer. Curr Probl Surg 2001, 38:387-480.
10. Robson M.E., Chappuis P.O., Satagopan J., et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004, 6:R8-R17.
11. Seynaeve C., Verhoog L.C., van de Bosch L.M., et al. Ipsilateral breast tumor recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 2004, 40:1150-1158.
12. Hall J.M., Lee M.K., Newman B., et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
13. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
14. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
15. Venkitaraman A. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
16. Pierce L.J., Strawderman M., Narod S.A., et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000, 18:3360-3369.
17. Shanley S., McReynolds K., Ardern-Jones A., et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006, 23:7025-7032.
18. Garcia-Etienne C.A., Barile M., Gentilini O.D., et al. Breast conserving surgery in BRCA1/2 mutation carriers: Are we approaching an answer?. Ann Surg Oncol 2009, 16:3380-3387.
19. Robson M., Levin D., Federici M., et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999, 91:2112-2117.
20. Haffty B.G., Harrold E., Khan A.J., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002, 359:1471-1477.
21. Kirova Y.M., Savignoni A., Sigal-Zafrani B., et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers?. Long-term results and review of the literature. Breast Cancer Res Treat 2010, 120:119-126.
22. Pierce L.J., Levin A.M., Rebbeck T.R., et al. Ten year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage. I/II breast cancer. J Clin Oncol 2006, 24:2437-2443.
23. Kirova Y.M., Stoppa-Lyonnet D., Savignoni A., et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005, 41:2304-2311.
24. Rebbeck T., Lynch H., Neuhausen S., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.
25. Kauff N.D., Domchek S.M., Friebel T.M., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter prospective study. J Clin Oncol 2008, 26:1331-1337.
26. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited muations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. JAMA 2001, 286:2251-2256.
27. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93:1633-1637.
28. Meijers-Heijboer H., van Geel B., van Putten W., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159-164.
29. Heemskerk B., Brekelmans C., Menke-Pluymers M., et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: Long-term experiences at the Rotterdam family cancer clinic. Ann Surg Oncol 2007, 14:3335-3344.
30. Rebbeck T., Friebel T., Lynch H., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The Prose Study Group. J Clin Oncol 2004, 22:1055-1062.
31. El-Tamer M., Russo D., Troxel A., et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 2004, 11:157-164.
32. Eccles D., Simmonds P., Goddard J., et al. Familial breast cancer: An investigation into the outcome of treatment for early stage disease. Fam Cancer 2001, 1:65-72.
33. Pierce L.J., Phillips K.-A., Griffith K.A., et al. Local therapy in BRCA1/2 carriers with operable breast cancer: Comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010, 121:389-398.
34. Hoonig M.J., Aleman B., Hauptmann M., et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol 2008, 26:5561-5568.
35. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in the BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328-2335.
36. Robson M., Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 2007, 357:154-162.
37. Limacher J.M., Frebourg T., Natarajan-Ame S., et al. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001, 96:238-242.
38. Lu C., El-Deiry W.S. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009, 14:597-606.
39. Pollard J.M., Gatti R.A. Clinical radiation sensitivity with DNA repair disorders: An overview. Int J Radiat Oncol Biol Phys 2009, 74:1323-1331.
40. Ho A.Y., Atencio D.P., Peters S., et al. Genetic predictors of adverse radiotherapy effects: The Gene-PARE project. Int J Radiat Oncol Biol Phys 2006, 65:646-655.
41. Iannuzzi C.M., Atencio D.P., Green S., et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 2002, 52:606-613.
42. Meyer A., John E., Dork T., et al. Breast cancer in female carriers of ATM gene alterations: Outcome of adjuvant radiotherapy. Radiother Oncol 2004, 72:319-323.
43. Edvardsen H., Tefre T., Jansen L., et al. Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiol Oncol 2007, 2:25.
44. Bremer M., Klopper K., Yamini P., et al. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: No observation of increased radiation-induced acute or late effects. Radiother Oncol 2003, 69:155-160.
45. Bernstein J.L., Haile R.W., Stovall M., et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's Environmental Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 2010, 102:475-483.
46. Meyer A., Dork T., Sohn C., et al. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy. Radiother Oncol 2007, 82:349-353.
47. Broeks A., de Witte L., Nooijen A., et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004, 83:91-93.
48. Nusbaum R., Vogel K.J., Ready K. Susceptibility to breast cancer: Hereditary syndromes and low penetrance genes. Breast Dis 2006, 27:21-50.
49. Ripperger T., Gadzicki D., Meindl A., et al. Breast cancer susceptibility: Current knowledge and implications for genetic counselling. Eur J Hum Genet 2009, 17:722-731.
50. Schroth W., Goetz M.P., Hamann U., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436.
51. Frank B., Hemminki K., Bermejo J.L., et al. TP53-binding protein variants and breast cancer risk: A case-control study. Breast Cancer Res 2005, 7:R502-R505.
52. Hirata H., Hinoda Y., Kikuno N., et al. Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009, 181:1907-1912.
53. Ma F., Sun T., Shi Y., et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with gefitinib. Lung Cancer 2009, 66:114-119.
54. Ma H., Hu Z., Zhai X., et al. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 2006, 27:766-771.
55. Krupa R., Synowiec E., Pawlowska E., et al. Polymorphism of the homologous recombination repair genes Rad51 and XRCC3 in breast cancer. Exp Mol Pathol 2009, 87:32-35.
56. Yuan X., Liao Z., Liu Z., et al. Single nucleotide polymorphism at rs1982073: T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009, 27:3370-3378.
57. Haffty BG, Goyal S, Kulkarni DA, et al: Evaluation of single nucleotide polymorphisms (SNP) in the P53 binding proteins 1 (TP53BP1) gene in breast cancer patients treated with breast conserving surgery and whole breast irradiation (BCS+RT). Int J Radiation Oncol Biol Phys (in press).